# Patent Watch: Curio Targets Sleep With Oral Cannab

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/patent-watch-patent-watch-curio-targets-sleep-with-oral-ca-2026-10-04/
> **Published:** 2026-10-04T09:38:13-04:00 | **Last Modified / Clinically Audited:** 2026-10-06T11:51:40-04:00
> **Clinical Summary:** The application claims oral pharmaceutical compositions containing cannabinoid active ingredients for treating sleep disorders, with the classifications in

---

PATENT WATCH
 US20260263486A1
 
 

# Patent Watch: Curio Targets Sleep With Oral Cannabinoid Tablets

 
 **Assignee:** Curio IP, LLC
 **Inventors:** Edward M. Rudnic, Michael Bronfein
 **Published:** 2026-09-10
 
 

 
 Invention Summary & Claims
 

The application claims oral pharmaceutical compositions containing cannabinoid active ingredients for treating sleep disorders, with the classifications indicating an emphasis on tablet dosage forms. Specific cannabinoids, doses, excipients, release characteristics, and pharmacokinetic advantages are not identified in the supplied summary, limiting assessment of formulation novelty.

 

 

## Clinical Perspective & Therapeutic Significance

 

A standardized oral product could offer more reproducible dosing than many conventional cannabis edibles, although oral cannabinoids remain subject to delayed onset, first-pass metabolism, and variable bioavailability. Potential concerns include next-day sedation, cognitive or motor impairment, drug interactions, and THC-related adverse effects, depending on the active ingredients and dose.

 

## Intellectual Property & Market Landscape

 

Curio IP, LLC appears to be protecting a pharmaceutical-style position in the competitive cannabinoid sleep market. The commercial distinction from oils, capsules, gummies, and other widely available products will depend on whether the patent claims defensible dose ratios, excipient systems, release profiles, or demonstrated pharmacokinetic consistency.

 
 **Official Source Document:** Review the primary patent disclosure and full claims on [Google Patents (US20260263486A1)](https://patents.google.com/patent/US20260263486A1/en).
 

 
 Editorial Commentary
 

This filing reflects continued movement toward standardized cannabinoid sleep medicines, but patent protection alone does not demonstrate better sleep outcomes or improved safety. Its practical importance will depend on formulation details, controlled clinical evidence, regulatory status, and reliable manufacturing.

 

 
 

### Frequently Asked Questions

 
 Could this oral cannabinoid formulation work better than a cannabis gummy or oil?
 It may provide more consistent dosing if manufactured to pharmaceutical standards, but superiority cannot be assumed without comparative pharmacokinetic and clinical studies.

 Does this patent application mean the treatment has succeeded in clinical trials?
 No. A published patent application describes intellectual property claims and does not establish that the product is safe, effective, approved, or supported by completed clinical trials.

 When might this cannabinoid sleep product become available?
 The publication does not establish a launch timeline. Availability would depend on patent prosecution, product development, manufacturing, clinical evidence, and the applicable state or federal regulatory pathway.

 

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.
 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Cannabis Consultation](https://cedclinic.com/book/)
 
 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).